Tomorrow Investor

REalloys Signs Definitive Long-Term Rare Earth Offtake Agreement with Critical Metals Corp. for 15% of Tanbreez Phase 1 Production

REalloys Secures Long-Term Rare Earth Offtake with Critical Metals | GlobeNewsWire

EUCLID, Ohio, May 21, 2026 (GLOBE NEWSWIRE) — REalloys Inc. (NASDAQ: ALOY) (“REalloys” or the “Company”) today announced that it has entered into a definitive long-term rare earth product offtake agreement (the “Offtake Agreement”) with Critical Metals Corp. (NASDAQ: CRML) (“CRML”) covering 15% of monthly Phase 1 production from CRML’s Tanbreez Project in southern Greenland, subject to a ±5% per-delivery operational variance. The Offtake Agreement was executed on May 20, 2026 and replaces and supersedes the non-binding letter of intent previously announced by the parties.

This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.

Brief Summary

REalloys Inc. has taken a significant step by securing a definitive long-term offtake agreement with Critical Metals Corp. This agreement covers 15% of monthly Phase 1 production from the Tanbreez Project. The deal was formally executed on May 20, 2026, reinforcing the partnership between these companies.

  • Operational Variance: ±5% per delivery.
  • Significant Partnership: A move to enhance supply chain reliability.
  • Market Impact: Expected positive implications for both companies’ stock value.

Why it matters: This agreement strengthens REalloys’ position in the rare earth market, providing stability and growth potential for stakeholders.

Read the Full Article

This is a summary of the press release. For the complete article and any additional details, please visit the original source.

Read Full Article

Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.

Tomorrow Investor
The Tomorrow Investor

Markets research for retail investors

Independent coverage of small-cap equities, biotech catalysts, and emerging market opportunities.